Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Upadacitinib open-label extension in adults with moderate to severe atopic dermatitis after M16-046
NL-OMON55265Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of upadacitinib in atopic dermatitis (AD), sponsored by AbbVie Inc. Primary endpoints: Treatment-emergent adverse events, Serious adverse events and 3 more. Started May 2020; status: completed.
02
Drugs
upadacitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NL-OMON55265.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55265.